NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals

Core Insights - NeOnc Technologies Holdings, Inc. has announced a significant milestone in its partnership with Quazar Investment, with a $50 million strategic partnership set to close by October 23, 2025 [1][4] - The partnership aims to enhance clinical trials, regulatory filings, and infrastructure development in the UAE and the broader MENA region [2][3] Company Overview - NeOnc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, with a drug development platform that includes NEO100 and NEO212, both in Phase II clinical trials [5] - The company has a patent portfolio extending to 2038, covering various drug candidates and delivery methods [5] Partnership Details - The partnership with Quazar Investment, a prominent Abu Dhabi-based firm with over $3.3 billion in assets, includes a $15 million allocation for Phase 2B clinical trials and infrastructure development [4] - NuroMENA Holdings, NeOnc's subsidiary, was incorporated in the Abu Dhabi Global Market on August 6, 2025, fulfilling the requirements for the partnership [3]